Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins, ‘Can We Cure Cancer with Artificial Intel...
August 14 2020 - 8:30AM
via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
today announces that Mark Collins, Ph.D., chief innovation officer
of its Helomics subsidiary, recently appeared on DojoLIVE!, a
lively podcast and interview forum that brings together a broad
roster of technology, business and thought leaders from a wide
range of software companies and startups.
The broadcast, titled ‘Can We Cure Cancer With Artificial
Intelligence?’, is available for on-demand viewing on the DojoLIVE!
website.
As noted during the interview, Collins possesses a passion for
applying science to build high-tech life-science products and
services that impact the search for new medicines. He feels that
Helomics, a division of Predictive Oncology, is uniquely positioned
to deliver on this goal.
Helomics aims to improve outcomes for the cancer patients of
today and in the future by harnessing the power of the patient’s
own living tumor. The company uses its unique clinically validated
Tumor Drug Response Profiling (TDRP) platform to generate a
comprehensive profile of the patient tumor to guide the oncologist
in individualizing treatment. In use for 15+ years, this platform
has generated drug response and genomic profiles on over 150,000
tumors – the largest knowledgebase of its kind in the world.
Helomics is leveraging this unique TDRP platform and huge
knowledge base to pioneer the development of AI-driven models of
tumor drug response and outcome that, in partnership with
pharmaceutical companies, will enable lower cost, faster and
smarter discovery of new therapies. Furthermore, once validated,
these AI-models will be used as clinical decision support tools to
help clinicians individualize cancer treatment with current
therapies.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Domestic, International and other), which contain four
subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline
Europe. Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor™, patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its
clients’ specific needs.
Predictive Oncology’s TumorGenesis subsidiary is developing a
new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still
growing inside a patient. Its proprietary Oncology Discovery
Technology Platform kits will assist researchers and clinicians to
identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified they can be used in TumorGenesis’
Oncology Capture Technology Platforms, which isolate and help
categorize an individual patient’s heterogeneous tumor samples to
enable the development of patient specific treatment options.
Helomics and TumorGenesis are focused on ovarian cancer. Predictive
Oncology’s Skyline Medical division markets its patented and FDA
cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through
both domestic and international divisions. The company has achieved
sales on five of the seven continents through both direct sales and
distributor partners. For more information, please
visit www.Predictive-Oncology.com.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company’s SEC filings. These risks
and uncertainties could cause the company’s actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
InvestorBrandNetwork (IBN) Los Angeles, California
www.InvestorBrandNetwork.com 310.299.1717 Office
Editor@InvestorBrandNetwork.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024